Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been granted a European patent titled "Regulation of Antigen Presentation." The patent issued on December 21, 2005 relates to the use of Ii-Key peptides in regulating antigen presentation. It broadly covers the use of Ii-Key in potential immunotherapy treatments of cancer and infectious diseases.
